Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;141(12):2459-72.
doi: 10.1017/S095026881300191X. Epub 2013 Aug 7.

Resistant gram-negative infections in the outpatient setting in Latin America

Collaborators, Affiliations
Review

Resistant gram-negative infections in the outpatient setting in Latin America

M J C Salles et al. Epidemiol Infect. 2013 Dec.

Abstract

Latin America has a high rate of community-associated infections caused by multidrug-resistant Enterobacteriaceae relative to other world regions. A review of the literature over the last 10 years indicates that urinary tract infections (UTIs) by Escherichia coli, and intra-abdominal infections (IAIs) by E. coli and Klebsiella pneumoniae, were characterized by high rates of resistance to trimethoprim/sulfamethoxazole, quinolones, and second-generation cephalosporins, and by low levels of resistance to aminoglycosides, nitrofurantoin, and fosfomycin. In addition, preliminary data indicate an increase in IAIs by Enterobacteriaceae producing extended-spectrum β-lactamases, with reduced susceptibilities to third- and fourth-generation cephalosporins. Primary-care physicians in Latin America should recognize the public health threat associated with UTIs and IAIs by resistant Gram-negative bacteria. As the number of therapeutic options become limited, we recommend that antimicrobial prescribing be guided by infection severity, established patient risk factors for multidrug-resistant infections, acquaintance with local antimicrobial susceptibility data, and culture collection.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Prevalence (and type) of extended spectrum β-lactamases harboured by K. pneumoniae1 and E. coli2 in Latin American clinical isolates during the late 1990s [32].
Fig. 2.
Fig. 2.
Percentage (no. of isolates) of urinary tract E. coli isolates collected from (a) women and (b) men in Latin America (2010 PAHO report) that were resistant to trimethoprim/sulfamethoxazole1, ciprofloxacin2, and the second-generation cephalosporin cefuroxime3 [39]. * Data from the 2009 PAHO report [38] is given for this country because 2010 data were not reported; † all adults (women and men).
Fig. 3.
Fig. 3.
Antimicrobial susceptibilities of ESBL-producing E. coli and K. pneumoniae intra-abdominal isolates in Latin America (2002–2008). Susceptibilities are based on in vitro minimum inhibitory concentration data. (Reprinted from Villegas et al. [42], copyright © 2011, with permission from Elsevier.)
Fig. 4.
Fig. 4.
Proportion of E. coli isolates from intra-abdominal infections in Latin America that were extended-spectrum β-lactamase positive (SMART, 2008–2009) [43].

References

    1. Fornasini M, et al. Trimethoprim-resistant Escherichia coli in households of children attending day care centers. Journal of Infectious Diseases 1992; 166: 326–330. - PubMed
    1. Reves RR, et al. Risk factors for fecal colonization with trimethoprim-resistant and multiresistant Escherichia coli among children in day-care centers in Houston, Texas. Antimicrobial Agents and Chemotherapy 1990; 34: 1429–1434. - PMC - PubMed
    1. McKeon DM, Calabrese JP, Bissonnette GK. Antibiotic resistant Gram-negative bacteria in rural groundwater supplies. Water Research 1995; 29: 1902–1908.
    1. Woerther PL, et al. Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. Journal of Infectious Diseases 2010; 202: 515–523. - PubMed
    1. Hawkey PM, Jones AM. The changing epidemiology of resistance. Journal of Antimicrobial Chemotherapy 2009; 64 (Suppl. 1): 3–10. - PubMed

Publication types

MeSH terms

Substances